Why RWE programs fail under regulatory scrutiny — and what leaders can do about it
FDA has made its expectations for RWE clearer and more structured through recent guidance and...
When billed and allowed amounts aren’t enough: HealthVerity proprietary market cost offering in taXonomy
A better way to measure healthcare costs in closed claims data This is the second post in our four-part taXonomy X blog series (part 1 here), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically,...
HPV vaccination trends from 2016 to 2025: Progress and missed opportunities
by: Alexandra Miller, MPH Human papillomavirus (HPV) is one of the most common sexually...
The Missing Pieces: How Rare Disease Diagnoses Come Together
Rare diseases may be individually uncommon, but collectively they affect an estimated 30 million...
Disrupting Healthcare Audiences: A new standard for precision and accuracy
"Healthcare audience targeting has changed fast, and expectations have climbed even faster." As...
.png)
Building guardrails for AI-driven real-world data programs
AI is rapidly reshaping how real-world data (RWD) is generated and analyzed across healthcare...
5 questions RWE & HEOR teams should ask data vendors in an RFP
RWE and HEOR teams face increasing pressure to produce evidence that holds up beyond internal...
Primary biliary cholangitis: Disease burden, treatments and RWD gaps
Understanding PBC and today’s treatment landscape Primary biliary cholangitis (PBC) is a chronic...
Insights in healthcare marketing start with truth, not inference
Healthcare marketing has reached an inflection point and for years, success was defined by reach:...
Measuring psoriasis severity, outcomes and comorbidities using real-world data
Capturing the true complexity of psoriasis in the real world Psoriasis is a common chronic...
How GLP-1 direct-to-consumer programs are distorting utilization trends
Closed claims no longer reflect real-world GLP-1 treatment patterns GLP-1 utilization continues to...